Dig Dis Sci: Colonoscopic fecal microbiota transplantation (FMT) is superior to the way enemas and nasal gastric tubes treat difficult Thyrobacteria refractive infections

Fecal microbiome transplantation (FMT) is the use of healthy confessions of feces into the target population, with the aim of changing the diversity of the patient's gut microbiome.
FMT has developed as the primary treatment for relapsed Thyrobacter difficile infection (CDI).
clinicians can use a variety of FMT modes, including colonoscopic infusion, nasal gastric tube (NGT), nasal heteroent intestinal tube (NDT), enema and, most recently, oral capsules.
study aims to assess differences in the efficacy of relapse CDI in four ways of colonoscopic infusion, capsule, enema and nasal gastric tube (NGT).
researchers collected clinical results from all databases about colonoscopy, capsules, enemas and NGT for FMT therapy of relapsed CDI.
researchers searched three databases: PubMed, EMBASE and CINAHL for all relevant literature between January 2000 and January 2018.
observational outcomes were the overall cure rate assessed using random effect models;
meta-analysis was included in 26 studies (1309 patients).
Used colonoscopic infusions in 16 studies (483 patients), NGT in five studies (149 patients), enemas in four studies (360 patients) and capsules in four studies (301 patients).
FMT cure rate caused by FMT infusion of colonoscopy was 94.8%, capsule 92.1%, enema 87.2% and NGT /NDT 78.1%.
in the subgroup analysis of FMT infusions in colonoscopy, the cure rate was not affected by donor differences: the mixing ratio was 94.5 percent, compared with 95.7 percent for unrelated relatives.
this study found that the CDI cure rate of FMT by colonoscopy infusion was better than that of enema and NGT, and that the CDI cure rate of FMT was comparable by colonoscopy infusion and capsule.